Tivicay PD (dolutegravir) 5mg Tablets for Oral Suspension, 60-count bottles, Each carton contains...

FDA Recall #D-0544-2024 — Class III — May 17, 2024

Recall #D-0544-2024 Date: May 17, 2024 Classification: Class III Status: Terminated

Product Description

Tivicay PD (dolutegravir) 5mg Tablets for Oral Suspension, 60-count bottles, Each carton contains one bottle of 60 tablets, one 30-mL dosing cup and one 10-mL oral dosing syringe, Rx Only, Mfd for: ViiV Healthcare Durham, NC, 27701, By: GlaxoSmithKline Durham, NC 27701, NDC 49702-255-37

Reason for Recall

Labeling: Incorrect Lot and/or Expiration Date: The carton has incorrect expiration of 2026-MAY*, whereas the correct expiration date, which is on the tablet bottle label, is 2025-APR.

Recalling Firm

GlaxoSmithKline LLC — Zebulon, NC

Classification

Class III — Not likely to cause adverse health consequences.

Product Type

Drugs

Product Quantity

463 Cartons

Distribution

Nationwide within the United States

Code Information

Lot #: AG4M, Labeled Expiry date on carton May 2026, correct Exp. Date 04/2025

Status

Terminated

Voluntary / Mandated

Voluntary: Firm initiated